CN Patent

CN116744922A — Nr2b-nmda受体nam在治疗抑郁症中的剂量方案

Assigned to Novartis AG · Expires 2023-09-12 · 3y expired

What this patent protects

本发明涉及化合物(I)或其药学上可接受的盐的剂量方案，其用于治疗由NR2B‑NMDA受体的负变构调节或抑制介导的疾病或病症，包括、但不限于严重抑郁障碍、难治性抑郁症和自杀倾向。本发明还涉及化合物(I)或其药学上可接受的盐在治疗在具有自杀观念与意图的的患者中的严重抑郁障碍中的用途。

USPTO Abstract

本发明涉及化合物(I)或其药学上可接受的盐的剂量方案，其用于治疗由NR2B‑NMDA受体的负变构调节或抑制介导的疾病或病症，包括、但不限于严重抑郁障碍、难治性抑郁症和自杀倾向。本发明还涉及化合物(I)或其药学上可接受的盐在治疗在具有自杀观念与意图的的患者中的严重抑郁障碍中的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN116744922A
Jurisdiction
CN
Classification
—
Expires
2023-09-12
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.